Oncogenic protein interfaces: Small molecules, big challenges

Nature Reviews Cancer

Volumn 14, Issue 4, 2014, Pages 248-262

  Nero, Tracy L ^a   Morton, Craig J ^a   Holien, Jessica K ^a   Wielens, Jerome ^a,b   Parker, Michael W ^a,c  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA CATENIN; BETA TUBULIN; BIRINAPANT; CABAZITAXEL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ERIBULIN; INDOCYANINE GREEN; INTERLEUKIN 2 RECEPTOR ALPHA; IXABEPILONE; LIPOCORTIN 2; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL X; RG 7112; RO 5045337; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINFLUNINE;

BREAST CANCER; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; MICROTUBULE ASSEMBLY; MOLECULAR DYNAMICS; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RADIOMETRY; REVIEW; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR DOCKING SIMULATION; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPS; SURFACE PROPERTIES;

EID: 84897443073     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3690     Document Type: Review

References (162)

1. Baker, N. M. & Der, C. J. Cancer: drug for an 'undruggable' protein. Nature 497, 577-578 (2013).
2. Raj, M., Bullock, B. N. & Arora, P. S. Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg. Med. Chem. 21, 4051-4057 (2013).
3. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
4. Garner, A. L. & Janda, K. D. Protein-protein interactions and cancer: targeting the central dogma. Curr. Top. Med. Chem. 11, 258-280 (2011).
5. Meier, C., Cairns-Smith, S. & Schulze, U. Can emerging drug classes improve R&D productivity? Drug Discov. Today 18, 607-609 (2013).
6. Zhang, Q. C. et al. Structure-based prediction of protein-protein interactions on a genome-wide scale. Nature 490, 556-560 (2012).
7. Janin, J., Bahadur, R. P. & Chakrabarti, P. Protein-protein interaction and quaternary structure. Q. Rev. Biophys. 41, 133-180 (2008).
8. Jubb, H., Higueruelo, A. P., Winter, A. & Blundell, T. L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 33, 241-248 (2012).
9. Valkov, E., Sharpe, T., Marsh, M., Greive, S. & Hyvonen, M. Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem. 317, 145-179 (2012).
10. Silvian, L., Enyedy, I. J. & Kumaravel, G. Inhibitors of protein-protein interactions: New methodologies to tackle this challenge. Drug Discov. Today, 10, E509-E515 (2013).
11. Arkin, M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol. 9, 317-324 (2005).
12. Villoutreix, B. O., Labbe, C. M., Lagorce, D., Laconde, G. & Sperandio, O. A leap into the chemical space of protein-protein interaction inhibitors. Curr. Pharm. Des. 18, 4648-4667 (2012).
13. Gao, M. & Skolnick, J. The distribution of ligand-binding pockets around protein-protein interfaces suggests a general mechanism for pocket formation. Proc. Natl Acad. Sci. USA 109, 3784-3789 (2012).
14. Heeres, J. T. & Hergenrother, P. J. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies. Chem. Soc. Rev. 40, 4398-4410 (2011).
15. Winter, A. et al. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 45, 383-426 (2012).
16. McFedries, A., Schwaid, A. & Saghatelian, A. Methods for the elucidation of protein-small molecule interactions. Chem. Biol. 20, 667-673 (2013).
17. Boisclair, M. D., Egan, D. A., Huberman, K. & Infantino, R. in Cancer Drug Discovery and Development: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (eds Teicher, B. A. & Andrews, P. A.) 23-39 (Humana Press Inc., 2004).
18. Pereira, D. A. & Williams, J. A. Origin and evolution of high throughput screening. Br. J. Pharmacol. 152, 53-61 (2007).
19. Baell, J. B. & Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
20. Hermann, J. C. et al. Metal impurities cause false positives in high-throughput screening campaigns. ACS Med. Chem. Lett. 4, 197-200 (2013).
21. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
22. Czabotar, P. E. & Lessene, G. Bcl-2 family proteins as therapeutic targets. Curr. Pharm. Des. 16, 3132-3148 (2010).
23. Tovar, C. et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 73, 2587-2597 (2013).
24. Petros, A. M. et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 49, 656-663 (2006).
25. Qian, J. et al. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal. Biochem. 328, 131-138 (2004).
26. Real, P. J. et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res. 64, 7947-7953 (2004).
27. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
28. Carry, J. C. & Garcia-Echeverria, C. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic. Bioorg. Med. Chem. Lett. 23, 2480-2485 (2013).
29. Vu, B. et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4, 466-469 (2013).
30. Ding, Q. et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem. 56, 5979-5983 (2013).
31. Dos-Santos, O. et al. 1017 human dedifferentiated liposarcomas growth inhibition by SAR299155, a potent and selective disruptor of the MDM2-p53 interaction. Eur. J. Cancer 48, S245-S246 (2012).
32. Grasberger, B. L. et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 48, 909-912 (2005).
33. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
34. Milroy, L. G., Brunsveld, L. & Ottmann, C. Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study. ACS Chem. Biol. 8, 27-35 (2013).
35. Rose, R. et al. Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions. Angew. Chem. Int. Ed. Engl. 49, 4129-4132 (2010).
36. Zhao, J. et al. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc. Natl Acad. Sci. USA 108, 16212-16216 (2011).
37. Thornberry, N. A. & Lazebnik, Y. Caspases: enemies within. Science 281, 1312-1316 (1998).
38. Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25-35 (2004).
39. Liu, Z. et al. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408, 1004-1008 (2000).
40. Oost, T. K. et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47, 4417-4426 (2004).
41. Shi, A. et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood 120, 4461-4469 (2012).
42. Grembecka, J. et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chem. Biol. 8, 277-284 (2012).
43. Yuriev, E. & Ramsland, P. A. Latest developments in molecular docking: 2010-2011 in review. J. Mol. Recognit. 26, 215-239 (2013).
44. Froufe, H. J., Abreu, R. M. & Ferreira, I. C. Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors. J. Enzyme Inhib. Med. Chem. 28, 569-575 (2013).
45. Khanna, M. et al. Targeting multiple conformations leads to small molecule inhibitors of the uPAR.uPA protein-protein interaction that block cancer cell invasion. ACS Chem. Biol. 6, 1232-1243 (2011).
46. Villoutreix, B. O. et al. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr. Pharm. Biotechnol. 9, 103-122 (2008).
47. Bowman, A. L., Nikolovska-Coleska, Z., Zhong, H., Wang, S. & Carlson, H. A. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J. Am. Chem. Soc. 129, 12809-12814 (2007).
48. Nikolovska-Coleska, Z. et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 47, 2430-2440 (2004).
49. Enyedy, I. J. et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 44, 4313-4324 (2001).
50. Ivanov, A. A., Khuri, F. R. & Fu, H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 34, 393-400 (2013).
51. Ewing, T. J., Makino, S., Skillman, A. G. & Kuntz, I. D. DOCK. 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15, 411-428 (2001).
52. Bajwa, N., Liao, C. & Nikolovska-Coleska, Z. Inhibitors of the anti-Apoptotic Bcl-2 proteins: a patent review. Expert Opin. Ther. Pat. 22, 37-55 (2012).
53. Boonstra, M. C. et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr. Pharm. Des. 17, 1890-1910 (2011).
54. Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009).
55. Reddy, T. R., Li, C., Fischer, P. M. & Dekker, L. V. Three-dimensional pharmacophore design and biochemical screening identifies substituted 1, 2, 4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction. ChemMedChem. 7, 1435-1446 (2012).
56. Corradi, V. et al. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3sigma case. Bioorg. Med. Chem. Lett. 21, 6867-6871 (2011).
57. Fry, D. et al. Design of libraries targeting protein-protein interfaces. ChemMedChem. 8, 726-732 (2013).
58. Koes, D. et al. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS ONE 7, e32839 (2012).
59. Sakkiah, S., Thangapandian, S., John, S. & Lee, K. W. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Eur. J. Med. Chem. 46, 2937-2947 (2011).
60. Phipps, K. D., Surette, A. P., O'Connell, P. A. & Waisman, D. M. Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res. 71, 6676-6683 (2011).
61. Takahashi, S. et al. Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption. J. Biol. Chem. 269, 28696-28701 (1994).
62. Shang, J. et al. S100A10 as a novel biomarker in colorectal cancer. Tumour Biol. 34, 3785-3790 (2013).
63. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267, 727-748 (1997).
64. Mustata, G. et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J. Med. Chem. 52, 1247-1250 (2009).
65. Chiang, Y. K. et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J. Med. Chem. 52, 4221-4233 (2009).
66. Seifert, M. H. J., Wolf, K. & Vitt, D. Virtual high-throughput in silico screening. BIOSILICO 1, 143-149 (2003).
67. Hajduk, P. J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature Rev. Drug Discov. 6, 211-219 (2007).
68. Sun, C., Petros, A. M. & Hajduk, P. J. Fragment-based lead discovery: challenges and opportunities. J. Comput. Aided Mol. Des. 25, 607-610 (2011).
69. Hajduk, P. J., Galloway, W. R. & Spring, D. R. Drug discovery: A question of library design. Nature 470, 42-43 (2011).
70. Scott, D. E., Coyne, A. G., Hudson, S. A. & Abell, C. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51, 4990-5003 (2012).
71. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-Affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
72. Hubbard, R. E. Fragment approaches in structure-based drug discovery. J. Synchrotron Radiat. 15, 227-230 (2008).
73. Fischer M. & Hubbard, R. E. Fragment-based ligand discovery. Mol. Interv. 9, 22-30 (2009).
74. Erlanson, D. A. Introduction to fragment-based drug discovery. Top. Curr. Chem. 317, 1-32 (2012).
75. Davis, B. J. & Erlanson, D. A. Learning from our mistakes: the 'unknown knowns' in fragment screening. Bioorg. Med. Chem. Lett. 23, 2844-2852 (2013).
76. Erlanson, D. A., McDowell, R. S. & O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 47, 3463-3482 (2004).
77. Hubbard, R. E. & Murray, J. B. Experiences in fragment-based lead discovery. Methods Enzymol. 493, 509-531 (2011).
78. Patrone, J. D. et al. Discovery of protein-protein interaction inhibitors of replication protein A. ACS Med. Chem. Lett. 4, 601-605 (2013).
79. Frank, A. O. et al. Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. J. Med. Chem. 56, 9242-9250 (2013).
80. Lepre, C. A. Practical aspects of NMR-based fragment screening. Methods Enzymol. 493, 219-239 (2011).
81. Badger, J. Crystallographic fragment screening. Methods Mol. Biol. 841, 161-177 (2012).
82. Chilingaryan, Z., Yin, Z. & Oakley, A. J. Fragment-based screening by protein crystallography: successes and pitfalls. Int. J. Mol. Sci. 13, 12857-12879 (2012).
83. Danielson, U. H. Fragment library screening and lead characterization using SPR biosensors. Curr. Top. Med. Chem. 9, 1725-1735 (2009).
84. Navratilova, I., Besnard, J. & Hopkins, A. L. Screening for GPCR ligands using surface plasmon resonance. ACS Med. Chem. Lett. 2, 549-554 (2011).
85. Silvestre, H. L., Blundell, T. L., Abell, C. & Ciulli, A. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc. Natl Acad. Sci. USA 110, 12984-12989 (2013).
86. Bower, J. F. & Pannifer, A. Using fragment-based technologies to target protein-protein interactions. Curr. Pharm. Des. 18, 4685-4696 (2012).
87. Turnbull, A. P. & Boyd, S. M. Targeting cancer using fragment based drug discovery. Anticancer Agents Med. Chem. 12, 40-48 (2012).
88. Boettcher, A. et al. Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12. J. Biomol. Screen. 15, 1029-1041 (2010).
89. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
90. Petros, A. M. et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett. 20, 6587-6591 (2010).
91. Lessene, G. et al. Structure-guided design of a selective BCL-XL inhibitor. Nature Chem. Biol. 9, 390-397 (2013).
92. Aguirre, C. et al. BcL-xL conformational changes upon fragment binding revealed by NMR. PLoS ONE 8, e64400 (2013).
93. Erlanson, D. A., Wells, J. A. & Braisted, A. C. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33, 199-223 (2004).
94. Arkin, M. R. et al. Binding of small molecules to an adaptive protein-protein interface. Proc. Natl Acad. Sci. USA 100, 1603-1608 (2003).
95. Raimundo, B. C. et al. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J. Med. Chem. 47, 3111-3130 (2004).
96. Renner, S. et al. Recent trends and observations in the design of high-quality screening collections. Future Med. Chem. 3, 751-766 (2011).
97. Thomas, C. E. & Will, Y. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Expert Opin. Drug Discov. 7, 109-122 (2012).
98. Makley, L. N. & Gestwicki, J. E. Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem. Biol. Drug Des. 81, 22-32 (2013).
99. Barker, A., Kettle, J. G., Nowak, T. & Pease, J. E. Expanding medicinal chemistry space. Drug Discov. Today 18, 298-304 (2013).
100. Waldmann, T. A. Immunotherapy: past, present and future. Nature Med. 9, 269-277 (2003).
101. Dimitrov, D. S. Therapeutic proteins. Methods Mol. Biol. 899, 1-26 (2012).
102. De Souza, E. B., Cload, S. T., Pendergrast, S. P. & Sah, D. W. Y. Novel therapeutic modalities to address nondrugable protein interaction targets. Neuropsychopharmacology 34, 142-158 (2009).
103. Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1-9 (2011).
104. Miller, M. J., Foy, K. C. & Kaumaya, P. T. P. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Disc. Med. 15, 166-176 (2013).
105. Tomlinson, I. M. Next-generation protein drugs. Nature Biotech. 22, 521-522 (2004).
106. Nelson, A. L., Dhimolea, E. & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nature Rev. Drug Discov. 9, 767-774 (2010).
107. Flego, M., Ascione, A., Cianfriglia, M. & Vella, S. Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases. BMC Med. 11, 4 (2013).
108. Otvos, L. Jr Peptide-based drug design: here and now. Methods Mol. Biol. 494, 1-8 (2008).
109. Roy, S. et al. Peptide based molecules as protein-protein interaction inhibitors: tools for chemical genetics and therapy. Curr. Chem. Biol. 6, 145-163 (2012).
110. Souroujon, M. C. & Mochly-Rosen, D. Peptide modulators of protein-protein interactions in intracellular signaling. Nature Biotech. 16, 919-924 (1998).
111. Tan, T. T. & White, E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv. Exp. Med. Biol. 615, 81-104 (2008).
112. Sleebs, B. E. et al. Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL. J. Med. Chem. 56, 5514-5540 (2013).
113. Muppidi, A. et al. Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J. Am. Chem. Soc. 134, 14734-14737 (2012).
114. Paschke, M. Phage display systems and their applications. Appl. Microbiol. Biotechnol. 70, 2-11 (2006).
115. Fischer, P. M. & Lane, D. P. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol. Sci. 25, 343-346 (2004).
116. Garcia-Echeverria, C., Chene, P., Blommers, M. J. & Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43, 3205-3208 (2000).
117. Mehan, M. R. et al. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. Adv. Exp. Med. Biol. 735, 283-300 (2013).
118. Zhu, G. et al. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem. Commun. (Camb.) 48, 10472-10480 (2012).
119. Chen, C. H., Chernis, G. A., Hoang, V. Q. & Landgraf, R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl Acad. Sci. USA 100, 9226-9231 (2003).
120. Dastjerdi, K., Tabar, G. H., Dehghani, H. & Haghparast, A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell, SELEX. Biotechnol. Appl. Biochem. 58, 226-230 (2011).
121. Esposito, C. L. et al. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6, e24071 (2011).
122. Kim, M. Y. & Jeong, S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid. Ther. 21, 173-178 (2011).
123. Mahlknecht, G. et al. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc. Natl Acad. Sci. USA 110, 8170-8175 (2013).
124. Dassie, J. P. et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotech. 27, 839-849 (2009).
125. Majumder, P., Gomes, K. N. & Ulrich, H. Aptamers: from bench side research towards patented molecules with therapeutic applications. Expert Opin. Ther. Patents 19, 1603-1613 (2009).
126. Din, O. S. & Woll, P. J. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther. Clin. Risk Manag. 4, 149-162 (2008).
127. McMillan, K. et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl Acad. Sci. USA 97, 1506-1511 (2000).
128. Eyrisch, S. & Helms, V. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem. 50, 3457-3464 (2007).
129. Lo Conte, L., Chothia, C. & Janin, J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285, 2177-2198 (1999).
130. Clackson, T. & Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386 (1995).
131. DeLano, W. L., Ultsch, M. H., de Vos, A. M. & Wells, J. A. Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283 (2000).
132. Bogan, A. A. & Thorn, K. S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1-9 (1998).
133. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 (1992).
134. Clackson, T., Ultsch, M. H., Wells, J. A. & de Vos, A. M. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J. Mol. Biol. 277, 1111-1128 (1998).
135. Manion, M. K. et al. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J. Biol. Chem. 279, 2159-2165 (2004).
136. Czabotar, P. E. et al. Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J. Biol. Chem. 286, 7123-7131 (2011).
137. Okamoto, T. et al. Stabilizing the pro-Apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem. Biol. 8, 297-302 (2013).
138. Lee, E. F. et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 14, 1711-1713 (2007).
139. Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N. & Garcia, K. C. The structure of interleukin-2 complexed with its α receptor. Science 308, 1477-1480 (2005).
140. Thanos, C. D., DeLano, W. L. & Wells, J. A. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl Acad. Sci. USA 103, 15422-15427 (2006).
141. Thanos, C. D., Randal, M. & Wells, J. A. Potent small-molecule binding to a dynamic hot spot on IL-2. J. Am. Chem. Soc. 125, 15280-15281 (2003).
142. Glanzer, J. G. et al. A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A. Nucleic Acids Res. 41, 2047-2059 (2013).
143. Gang, E. J. et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene http://dx.doi.org/10.1038/onc.2013.169 (2013).
144. Emami, K. H. et al. A small molecule inhibitor of β-catenin/CREB- binding protein transcription [corrected]. Proc. Natl Acad. Sci. USA 101, 12682-12687 (2004).
145. Fulda, S. & Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nature Rev. Drug Discov. 11, 109-124 (2012).
146. Bellmunt, J. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol. 27, 4454-4461 (2009).
147. Ngan, V. K. et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 60, 5045-5051 (2000).
148. Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021 (2001).
149. Morris, P. G. Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs 21, 885-889 (2010).
150. Conlin, A., Fornier, M., Hudis, C., Kar, S. & Kirkpatrick, P. Ixabepilone. Nature Rev. Drug Discov. 6, 953-954 (2007).
151. Lee, F. Y. et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7, 1429-1437 (2001).
152. Weisberg, E. et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 24, 2100-2109 (2010).
153. Houghton, P. J. et al. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 636-639 (2012).
154. Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909-916 (2011).
155. Hwang, J. J. et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 16, 4038-4045 (2010).
156. O'Brien, S. M. et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113, 299-305 (2009).
157. Schimmer, A. D. et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 8295-8301 (2008).
158. Gore, M. E., Harrison, M. L. & Montes, A. New drug therapies for advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 7, 57-71 (2007).
159. Rini, B., Kar, S. & Kirkpatrick, P. Temsirolimus. Nat. Rev. Drug Discov. 6, 599-600 (2007).
160. Heist, R. S. et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J. Thorac. Oncol. 5, 1637-1643 (2010).
161. Liu, G. et al. An open-label, multicenter, phase I/II study of single-Agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15, 3172-3176 (2009).
162. Mita, A. C. et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15, 723-730 (2009).